-
UPDATE: Ladenburg Thalmann Lowers PT on GSV Capital, Sees Growth Opportunities
Wednesday, May 23, 2012 - 10:13amLadenburg Thalmann has published a research report on GSV Capital (NASDAQ: GSVC) and has lowered the price target from $20.25 to $17.75 as the company has opportunities for exposure in private, emerging growth companies. In the report, Ladenburg Thalmann writes, "According to recent data from...
Read More >> -
UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy
Thursday, May 17, 2012 - 10:44amLadenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation. In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we...
Read More >> -
UPDATE: Ladenburg Thalmann Reduces PT on Bioanalytical Systems to $2.25
Tuesday, May 15, 2012 - 9:17amAccording to a research report this morning, Ladenburg Thalmann reduces its PT on Bioanalytical Systems (NASDAQ: BASI) from $2.75 to $2.25 following disappointing Q2-2012. Ladenburg Thalmann stated, “The Company announced losing $1.86MM and $0.27 per share on revenue of $6.97MM as compared with...
Read More >> -
UPDATE: Ladenburg Thalmann Raises Prospect Capital's PT
Monday, May 14, 2012 - 8:41amAccording to a research report published this morning, Ladenburg Thalmann has increased Prospect Capital's (NASDAQ: PSEC) PT from $11 to $11.50. In the report, Ladenburg Thalmann commented, "During 3Q12 PSEC closed on $171 million of new and follow-on portfolio investments versus $155 million in...
Read More >> -
UPDATE: Ladenburg Thalmann Lowers Full Circle Capital's PT
Monday, May 14, 2012 - 8:32amAccording to a research report published this morning, Ladenburg Thalmann has lowered Full Circle Capital's (NASDAQ: FULL) PT from $8 to $7.50. Ladenburg Thalmann commented in the report, "FULL held its earnings call on May 11, 2012 and reported 3Q12 NOI per share of $0.18 which missed our $0.21...
Read More >> -
UPDATE: Ladenburg Thalmann Cuts PT to $37 on Chesapeake Midstream Partners; EPU Misses Consensus
Monday, May 14, 2012 - 8:12amLadenburg Thalmann reduces its price target from $38 to $37 on Buy-rated Chesapeake Midstream Partners (NYSE: CHKM) as the firm misses consensus estimates on Earnings Per Unit in Q1. Ladenburg Thalmann notes, "1Q12 Earnings Per Unit (EPU) Below Consensus But In-Line With Our Expectations. For...
Read More >> -
Thursday, May 10, 2012 - 12:02pm
Benzinga's Top Upgrades with Color for May 10, 2012
Listed below are Benzinga's Top Upgrades: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals (NASDAQ: KERX) to Buy: Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following yesterday's announcement of the perifosine data. Zerenex's Phase III program...
Read More >> -
Thursday, May 10, 2012 - 11:54am
Benzinga's Top Downgrades With Color for May 10, 2012
Listed below are today's Top Downgrades at Benzinga: ISI Group Downgrades Staples (NASDAQ: SPLS) to Sell: ISI Group commented, "We are downgrading Staples to Sell from Hold, as the stock has bounced 8% ytd, yet secular fundamentals have not improved, European headwinds remain, and our surveys...
Read More >> -
UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT
Thursday, May 10, 2012 - 10:54amAccording to a research report published this morning, Ladenburg Thalmann has upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, and established a $3 PT. In the report, Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following...
Read More >> -
UPDATE: Ladenburg Thalmann Downgrades AMAG Pharmaceuticals; Removes PT
Thursday, May 10, 2012 - 10:24amAccording to a research report published this morning, Ladenburg Thalmann has downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Buy to Neutral and removed its $19 PT. Ladenburg Thalmann commented in the report, "Our prior AMAG rating had been partially justified by expectations for a potential...
Read More >>
